Standout Papers

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Met... 2003 2026 2010 2018 2.1k
  1. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer (2003)
    James Chih‐Hsin Yang, Leah Haworth et al. New England Journal of Medicine
  2. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma (2010)
    Alice L. Yu, Andrew L. Gilman et al. New England Journal of Medicine

Immediate Impact

11 by Nobel laureates 12 from Science/Nature 121 standout
Sub-graph 1 of 16

Citing Papers

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
6 intermediate papers

Works of Helen X. Chen being referenced

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
2010 Standout
Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301
2006

Author Peers

Author Last Decade Papers Cites
Helen X. Chen 4050 3819 2512 83 8.7k
Elisabeth Buchdunger 4397 5588 2498 59 17.1k
Anthony Elias 5774 2124 3463 204 9.6k
Charles M. Baum 4641 5831 8095 70 12.6k
Emily K. Bergsland 6965 3096 1729 198 10.7k
Renaud Capdeville 2777 2949 2132 49 12.7k
Clara C. Chen 3203 1159 1599 97 8.7k
Hidefumi Sasaki 6305 4943 7199 143 11.7k
H. J. G. Bloom 2007 1304 1531 80 6.9k
Marcia S. Brose 4456 3514 2031 180 11.1k
David Lebwohl 5202 3408 3284 43 9.4k

All Works

Loading papers...

Rankless by CCL
2026